Farletuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Farletuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetFR-alpha
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6466H9928N1716O2020S42
Molar mass145.4 kg/mol
 ‹See TfM›☒N☑Y (what is this?)  (verify)

Farletuzumab (MORAb-003) is a monoclonal antibody[1] which is being investigated for the treatment of ovarian cancer.[2][3]

This drug was developed by Morphotek, Inc.

It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.

References[edit]